CagrilintideMetabolic Research PeptideSafety Rating 7/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors · per 10mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| Amino ClubBest $/mgCOA ✓ · 3P | $55.99 | $5.60 | May 14, 2026 | Buy → |
| Puratek PeptidesCOA ✓ · 3P | $65.66 | $6.57 | May 19, 2026 | Buy → |
| Puratek PeptidesCOA ✓ · 3POut of stock | $41.36 | $8.27 | May 19, 2026 | Buy → |
| Red River PeptidesCOA ✓ · 3PAvailable on backorder | $42.50 | $8.50 | May 19, 2026 | Buy → |
| Optimum FormulaCOA ✓ · 3P | $44.99 | $9.00 | May 14, 2026 | Buy → |
Overview
About Cagrilintide
Mechanism of action
Long-acting amylin receptor agonist; amylin is co-secreted with insulin; activates amylin receptors in the hypothalamus and brainstem; reduces food intake, slows gastric emptying, reduces body weight; complements GLP-1 mechanisms via separate pathways.
Safety profile
Nausea, vomiting, diarrhea, injection site reactions; generally well-tolerated; similar GI profile to GLP-1 class. Still in trials. · Phase III trials show good tolerability; GI side effects; injection site reactions
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Cagrilintide below your target.
Related pages
More on Cagrilintide
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- Long-acting fatty-acid-acylated amylin analogue with a 7-day half-life; combined with semaglutide 2.4 mg (CagriSema), produced ~25% mean body weight reduction in REIMAGINE Phase 2/3 — approaching surgical outcomes.
- Structural studies (2025) revealed cagrilintide engages amylin receptors 1 and 3 in distinct brainstem regions for satiety, complementing GLP-1 receptor engagement by semaglutide for additive weight loss.